Head Of Australia’s Bone Medical Ousted After Two Years
This article was originally published in PharmAsia News
Australia's Bone Medical biopharmaceutical company is losing its managing director of the past two years. Troels Jordansen lost his job in a restructuring of the company's board of directors, to be replaced soon by an unnamed person from the United States. Bone Medical, which concentrates on breakthrough treatments for bone and joint degeneration and related diseases, reported having less than $124,000 in cash at the end of the March quarter. (Click here for more
You may also be interested in...
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.